Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial

References

• Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout. Vol 23; 2005. Available from: www.nejm.org. Accessed September 8, 2023.
   Google Scholar
• Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63. doi:10.1186/ar2978
   PubMed Web of Science ®Google Scholar
• Sapankaew T, Thadanipon K, Ruenroengbun N, et al. Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials. BMC Nephrol. 2022;23(1). doi:10.1186/s12882-022-02850-3
   PubMed Web of Science ®Google Scholar
• Suzuki S, Yoshihisa A, Yokokawa T, et al. Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial. J Int Med Res. 2021;49(12):030006052110627. doi:10.1177/03000605211062770
   Web of Science ®Google Scholar
• Hainer BL, Matheson E, Wilkes RT Diagnosis, Treatment, and Prevention of Gout. Vol 90; 2014. Available from: www.aafp.org/afp. Accessed September 8, 2023.
   Google Scholar
• Neilson J, Bonnon A, Dickson A. Gout: diagnosis and management NICE guideline; 2022. Available from: www.nice.org.uk/guidance/ng219. Accessed September 8, 2023.
   Google Scholar
• Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum. 2020;50(3):S11–S16. doi:10.1016/j.semarthrit.2020.04.008
   PubMedGoogle Scholar
• Singh JA. Quality of life and quality of care for patients with gout. Curr Rheumatol Rep. 2009; 11 (2) :154–160.
   PubMedGoogle Scholar
• Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649–662. doi:10.1038/nrrheum.2015.91
   PubMed Web of Science ®Google Scholar
• Li Q, Li X, Wang J, et al. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements. BMJ Open. 2019;9(8):e026677. doi:10.1136/bmjopen-2018-026677
   PubMed Web of Science ®Google Scholar
• Pillinger MH, Mandell BF. Therapeutic approaches in the treatment of gout. Semin Arthritis Rheum. 2020;50(3):S24–S30. doi:10.1016/j.semarthrit.2020.04.010
   PubMedGoogle Scholar
• Flores NM, Nuevo J, Klein AB, Baumgartner S, Morlock R. The economic burden of uncontrolled gout: how controlling gout reduces cost. J Med Econ. 2019;22(1):1–6. doi:10.1080/13696998.2018.1532904
   PubMed Web of Science ®Google Scholar
• Jeon YK, Pearce F, Thong BYH, Aziz MIA, Aziz MIA. Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore. J Med Econ. 2020;23(8):838–847. doi:10.1080/13696998.2020.1757456
   PubMed Web of Science ®Google Scholar
• Kannangara DRW, Graham GG, Wright DFB, et al. Individualising the dose of allopurinol in patients with gout. Br J Clin Pharmacol. 2017;83(9):2015–2026. doi:10.1111/bcp.13307
   PubMed Web of Science ®Google Scholar
• Proudman C, Lester SE, Gonzalez-Chica DA, Gill TK, Dalbeth N, Hill CL. Gout flares, and allopurinol use: a population-based study. Arthritis Res Ther. 2019;21(1). doi:10.1186/s13075-019-1918-7
   Google Scholar
• Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273–1282. doi:10.3899/jrheum.080814
   PubMed Web of Science ®Google Scholar
• Schumacher HR, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, Phase III, randomized, double-blind, parallel-group trial. Arthritis Care Res. 2008;59(11):1540–1548. doi:10.1002/art.24209
   Web of Science ®Google Scholar
• Kamatani N, Fujimori S, Hada T, et al. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: Phase 3 clinical study. J Clin Rheumatol. 2011;17(4 Suppl 2). doi:10.1097/rhu.0b013e31821d36cc
   Web of Science ®Google Scholar
• Iqbal U, Siddiqui HU, Anwar H, Chaudhary A, Quadri AA. Allopurinol-induced granulomatous hepatitis: a case report and review of literature. J Investig Med High Impact Case Rep. 2017;5(3). doi:10.1177/2324709617728302
   Google Scholar
• Ng WL, Lim KS, Hariraj V, et al. Incidence of allopurinol-induced severe cutaneous adverse drug reaction in Malaysia. Br J Clin Pharmacol. 2022;88(8):3782–3788. doi:10.1111/bcp.15327
   PubMed Web of Science ®Google Scholar
• Gaffo AL, Saag KG Core evidence febuxostat: the evidence for its use in the treatment of hyperuricemia and gout; 2009. Available from: www.dovepress.com. Accessed September 8, 2023.
   Google Scholar
• Chen C, Chung W, Lin Y, Chang C, Chang S. Risk of Severe Adverse Reactions Related to Allopurinol and Febuxostat in Asians. Value Health. 2018;21:S106. doi:10.1016/j.jval.2018.07.801
   Web of Science ®Google Scholar
• Malaysia, Ministry of Health Clinical Practice GuidelinesManagement of Gout Malaysian Society of Rheumatology, Academy of Medicine Malaysia Malaysia Health Technology Assessment Section, Medical Development Division 2021.
   Google Scholar
• FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res. 2020;72(6):744–760. doi:10.1002/acr.24180
   PubMed Web of Science ®Google Scholar
• Jeong H, Choi E, Suh A, Yoo M, Kim B. Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea. Rheumatol Int. 2022;43(2):265–281. doi:10.1007/s00296-022-05222-0
   PubMed Web of Science ®Google Scholar
• Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American college of rheumatology guidelines for management of gout. part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431–1446. doi:10.1002/acr.21772
   PubMed Web of Science ®Google Scholar
• Zhang S, Xu T, Shi Q, et al. Cardiovascular safety of febuxostat and allopurinol in hyperuricemic patients with or without gout: a network meta-analysis. Front Med. 2021:8. doi:10.3389/fmed.2021.698437
   Web of Science ®Google Scholar
• Stephen H, Halpern M, Douglas J. Appendix: Jadad Scale for Reporting Randomized Controlled Trials: Evidence-Based Obstetric Anesthesia. Blackwell Publishing Ltd; 2007:237–238.
   Google Scholar
• Huang X, Du H, Gu J, et al. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. Int J Rheum Dis. 2014;17(6):679–686. doi:10.1111/1756-185X.12266
   PubMed Web of Science ®Google Scholar
• Xu S, Liu X, Ming J, et al. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia. Int J Rheum Dis. 2015;18(6):669–678. doi:10.1111/1756-185X.12648
   PubMed Web of Science ®Google Scholar
• Spina M, Nagy Z, Ribera JM, et al. FLORENCE: a randomized, double-blind, Phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol. 2015;26(10):2155–2161. doi:10.1093/annonc/mdv317
   PubMed Web of Science ®Google Scholar
• Zhang F, Liu Z, Jiang L, et al. A randomized double-blind, non-inferiority study of febuxostat versus allopurinol in hyperuricemic Chinese subjects with or without gout. Rheumatol Ther. 2019;6(4):543–557. doi:10.6084/m9.figshare.9771893
   PubMed Web of Science ®Google Scholar
• Yang N, Cao B. Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: a double-centre, randomized, controlled study. J Clin Pharm Ther. 2022;47(12):2214–2222. doi:10.1111/jcpt.13794
   PubMed Web of Science ®Google Scholar
• Goldfarb DS, MacDonald PA, Gunawardhana L, et al. Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary acid excretion and calcium stones. Clin J Am Soc Nephrol. 2013;8(11):1960–1967. doi:10.2215/CJN.01760213
   PubMed Web of Science ®Google Scholar
• Zhang S, Xie Q, Xie S, et al. The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): a network meta-analysis of randomized trials. Pharmacotherapy. 2021;41(9):781–791. doi:10.1002/phar.2609
   PubMed Web of Science ®Google Scholar
• Tien YY, Shih MC, Tien CP, Huang HK, Tu YK. To treat or not to treat? Effect of urate-lowering therapy on renal function, blood pressure and safety in patients with asymptomatic hyperuricemia: a systematic review and network meta-analysis. J Am Board Fam Med. 2022;35(1):140–151. doi:10.3122/jabfm.2022.01.210273
   PubMed Web of Science ®Google Scholar
• U.S National Library of Medicine. Febuxostat national center for biotechnology information; 2018. Available from: https://www/ncbi.nml.nih.gov/books/. Accessed May 31, 2023.
   Google Scholar
• Akari S, Nakamura T, Furusawa K, Miyazaki Y, Kario K. The reality of treatment for hyperuricemia and gout in Japan: a historical cohort study using health insurance claims data. J Clin Hypertens. 2022;24(8):1068–1075. doi:10.1111/jch.14539
   Web of Science ®Google Scholar
• Cardoso CS, Vieira AM, Oliveira AP. DRESS syndrome: a case report and literature review. BMJ Case Rep. 2011;2011:bcr0220113898. doi:10.1136/bcr.02.2011.3898
   PubMedGoogle Scholar
• Zeng M, Zhang M, Liu F, Yan W, Kong Q, Sang H. Drug eruptions induced by allopurinol associated with HLA-B*5801. Indian J Dermatol Venereol Leprol. 2015;81(1):43–45. doi:10.4103/0378-6323.148566
   PubMed Web of Science ®Google Scholar
• Villanueva-Paz M, Niu H, Segovia-Zafra A, et al. Critical review of gaps in the diagnosis and management of drug-induced liver injury associated with severe cutaneous adverse reactions. J Clin Med. 2021;10(22):5317. doi:10.3390/jcm10225317
   PubMed Web of Science ®Google Scholar
• U.S. National Library of Medicine. Allopurinol. National Center for Biotechnology Information; 2020. Available from: https://www/ncbi.nlm.nih.gov/books/. Accessed May 31, 2023.
   Google Scholar
• Markel A. Allopurinol-induced DRESS syndrome. IMAJ. 2005;7(10):656.
   Google Scholar
• Electronic Medicine Compendium, Allopurinol 300mg Tablets_SMPC_13SEP2018. https://www.medicines.org.uk/emc/product/9468/smpc/print. Accessed 14 May 2023.
   Google Scholar
• Electronic Medicine Compendium, Febuxostat 80 mg film-coated tablets_SMPC_24APR2023. https://www.medicines.org.uk/emc/product/10521/smpc/print 2018. Accessed14 May 2023.
   Google Scholar
• Singh JA, Richards JS, Chang E, Toupin-April K, Barton JL. Shared decision-making in gout treatment: a national study of rheumatology provider opinion and practice. Clin Rheumatol. 2021;40(2):693–700. doi:10.1007/s10067-020-05421-9
   PubMed Web of Science ®Google Scholar